Arsenic-induced Health Hazards: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Peter Tang and Version 1 by Abdulrahman Alsayegh.

Arsenic (As) is a naturally found crystalline metalloid with ubiquitous distribution throughout the earth’s crust. As exposure to the human food chain ecosystem comprises air, water, food, and soil. Daily diet contamination depends on the inorganic or organic forms, oxidation state, water solubility, and food matrix. The differentiation and categorization of different foods as sources of inorganic and organic As contamination in daily life is an important issue.

  • arsenic
  • health hazards
  • water

1. Introduction

As is a naturally found crystalline metalloid with ubiquitous distribution throughout the earth’s crust. As exposure to the human food chain ecosystem comprises air, water, food, and soil. Daily diet contamination depends on the inorganic or organic forms, oxidation state, water solubility, and food matrix. The differentiation and categorization of different foods as sources of inorganic and organic As contamination in daily life is an important issue. Industrialization, urbanization, and anthropogenic activities such as glassware, industrial chemicals, lead alloys, and pharmaceuticals manufacturing processes are prime causes of arsenic exposure in the environment. Heavy metal concentrations in all-natural water reservoirs exceed the cut-off of WHO’s safe limits for human health [1,2][1][2].
It is found that both organic and inorganic forms have no taste, odor, or color. Pentavalent arsenic (As (V) or arsenate) and trivalent arsenic (As (III) or arsenite), both in inorganic and organic forms, are present in natural ecosystems [3,4,5][3][4][5]. Inorganic arsenic (As (III) and As (V) or a combination of both) in ground water and biological activity transformation converts into arsenobetaine and different arsenosugars. Moreover, lipid-soluble arsenic forms, namely arsenolipids, have also been detected in fish and algae. Different As species can be seen in Table 1.
Table 1.
Different species of arsenic and their distribution in various foods with toxicities.

Different Species of Arsenic

Abbreviation

Distribution

References

Arsenocholine

AC

Arsenic species generally found in seafood and oxidized to arsenobetaine in a biological system.

[6]

In organic arsenic

iAs

Found in most foods and its presence in water is in low amounts.

[7]

Arsenite

As (III)

It is highly toxic in nature but present in lesser amounts in most foods.

[7]

Arsenate

As (V)

It is highly toxic in nature but present in lesser amounts in most foods and water.

[8,9][8][9]

Dimethylarsinate

DMA

Found in seafood and terrestrial foods and is a urine metabolite of iAs arsenosugars.

[10]

Dimethylarsinite

DMA (III)

It cannot be detected in food samples. It is a metabolite of iAs and can be seen in human urine samples but is highly toxic in nature.

[11]

Methylarsonate

MA

Found in seafood and terrestrial foods in very low amounts and is a metabolite of iAs that can be seen in urine.

[12]

Methylarsonite

MA (III)

It cannot be detected in food samples. It is a metabolite of iAs that can be seen in human urine samples but it is a toxic metabolite.

[13]

Arsenobetaine

Arsenosugar

AB

It is a major arsenic species and commonly found in seafood but is non-toxic in nature.

[7]

Trimethylarsonio

propionate

TMAP

Present in most foods. It is one of the major arsenic species.

[14]

Trimethylarsine oxide

TMAO

It is generally found in seafood and distributed in small amounts.

[11]

2. Arsenic Cellular Metabolism

iAs present in the human body is generally excreted through urine and bile [78][15]. Urinary arsenic measurements (iAs%, MMA%, and DMA%) act as indicators of arsenic metabolism and methylation capacity [79,80][16][17]. Trans-cellular and paracellular pathways are major modes of iAs transportation [81][18]. Cellular metabolism includes methylation in four forms, namely monomethylarsonic acid (MMAV), monomethylarsonous acid (MMAIII), dimethylarsinic acid (DMAV), and dimethylarsinous acid (DMAIII). Among the different forms, MMAIII is reported as the most cytotoxic [82][19]. MMAIII species can inhibit mitochondrial I and III processes by electron escape through the electron transport chain, leading to the production of reactive oxygen species (ROS) and reactive nitrogen (RNS). Free radical production leads to DNA damage and impaired gene expression [83][20]. Enzymatic methylation occurs by way of the primary enzyme involved in As metabolism, called arsenic (3+) methyltransferase (AS3MT), and endogenous reducing agents such as thioredoxin (Trx) and glutathione (GSH) [84,85][21][22].
Arsenic has an affinity with thiol groups, inhibiting the catalytic activity of an enzyme by binding with thiol-containing active sites. GSH plays an important role in transforming arsenate (AsV) to arsenite (AsIII); the arsenite form has a shorter half-life in comparison to arsenate. Antioxidants act as electron donors during the reduction of pentavalent to trivalent arsenic due to their high affinity to GSH [86][23]. Arsenic–thiol interaction consequences include MMAIII inhibiting GSH reductase and thioredoxin reductase [87][24]. Arsenate produces glucose-6-arsenate and 6-arsenogluconate by the substitution of phosphate in glucose and gluconate and forms glucose-6-arsenate and 6-arsenogluconate, analogous to glucose-6-phosphate and 6-phospho-gluconate, respectively. Glucose-6-arsenate binds to glucose-6-phosphate dehydrogenase and a high concentration of arsenate inhibits hexokinase activity through negative feedback mechanisms during glycolysis. Arsenic inhibits the conversion of pyruvate to acetyl coenzyme A (acetyl-coA), which leads to diminished cellular glucose uptake, gluconeogenesis, the oxidation of fatty acid, and further acetyl-CoA production. Mitochondria is an important cellular target by arsenite and free radical production, lipid peroxidation, H2O2 production, and mitochondrial swelling. Arsenic induces the formation of superoxide anion radicals such as singlet oxygen, the peroxyl radical, hydroxyl radicals, NO, H2O2, dimethyl-arsinic-peroxyl radicals, and dimethylarsinic radicals in a dose-dependent manner and consequently leads to health complications [88][25].

3. Arsenic-induced Health Hazards

3.1. Major Organ Damage and Chronic Disease Development

Human body organs are typically distressed by As poisoning. Major organs susceptible to As toxicity are the kidneys, lungs, liver, and skin. Severe As toxicity leads to coma and death. Target organ damage (TOD) depends on the ingested arsenite (As+3) content in the body. Firstly, an initial sign of skin changes involves its binding with keratin and accumulation in hair and nails. The appearance of keratosis is a common early sign of arsenic exposure. Recently, squamous cell carcinoma (SQCC), melanosis, and keratosis to Bowen’s disease have been reported in Asian countries, especially in India, Nepal, and Bangladesh [89,90][26][27]. Increased monomethylarsonate (MMA)% and decreased dimethylarsinate (DMA)% of arsenic species are directly proportional to a higher risk of bladder, pulmonary, and skin cancers. Carcinogenic and chromatin alteration have been exhibited due to transcription initiation and gene sequencing. The cellular genomic modification of deoxyribonucleic acid (DNA) methylation and the post-transcriptional modification (PTMs) of histone proteins lead to tumors and benign dysplasia. Arsenic induces miRNA gene expression that affects polymerase elongation and the recruitment of splicing regulatory factors and leads to carcinogenicity [8,91][8][28].
Drinking water iAs is nearly 80–90% absorbed by the intestine and protein transporters of arsenic such as aquaporin-10, GLUT-5, and organic anion-transporting polypeptides (OATPB) in the gut epithelium [92][29]. As exposure can lead to developing a risk of nonalcoholic fatty liver diseases among adolescents [93][30]. As is a promoter of inflammation, oxidative stress, and endothelial dysfunction by different mechanisms including the activation of transcription factors such as protein-1 and nuclear factor κβ [94,95][31][32]. The mechanisms of carcinogenesis take place through multiple pathways, including the perturbation of gut microbiota, genotoxicity, and epigenetic dysregulation [96,97,98][33][34][35]. The conjugation of arsenic with glutathione forms arsenic triglutathione, and the methylation of arsenic produces dimethylarsenic glutathione and enters bile and the bloodstream. This unstable species changes into the volatile compound dimethylarsine. As is transported via RBCs and is stored as protein-bound trivalent dimethyl arsenicals in different organs of the body [7]. As exhibits carcinogenic effects in the liver and produces hepatocellular carcinoma through DNA repair inhibition and the development of micronuclei and epigenetic dysregulation [96,99][33][36]. Different As species-linked health effects have been mentioned in Table 2.
Table 2.
Various arsenic species and associated health hazards.

Arsenic Chemical Forms

Health Effects

References

Inorganic arsenic (AsIII and AsV)

Cancer

[100][37]

Chronic diseases

[101,102][38][39]

Mutation

[103][40]

DNA damage

[104][41]

Mitochondrial dysfunction

[105][42]

Reduces bone mineralization

[106][43]

Hyperglycemia

[107][44]

Lipid disorders

118][55]. Chronic exposure to As leads also to several other clinical manifestations such as hypercalciuria, glomerulonephritis, acute tubular necrosis, albuminuria, nephrocalcinosis, and renal papillae necrosis [81][18]. The development of incipient nephropathy and the incidence of chronic kidney disease (CKD) have been reported due to As-induced injury of the nephron [119][56]. As nephritis and renal damage occur due to direct podocyte injury and endothelial dysfunction and increase the expression of the vascular cell adhesion molecule 1 (VCAM-1) [120,121][57][58]. The direct effects of arsenic species and metabolites on chronic diseases with their respective mechanisms are listed in Table 3.
Table 3.
Direct effects of arsenic species and their metabolites with respective mechanisms in different chronic diseases.

Arsenic Species

Direct Toxic Effect and Target Organ Damage (TOD)

Molecular Mechanisms

References

Inorganic arsenic in drinking water and rice

Skin cancer

Differentiation and generation of cancer stem cells

[122,123][59][60]

Coronary artery disease and cardiac muscle damage

Cardiac tissue hypoxia and inflammation

[124]

[

128][65]

Arsenite (AsIII)

Insulin resistance and

metabolic syndrome

Diminished translocation of GLUT4

[129][66]

MMA (Monomethylarsonic acid)

Breast cancer

Endocrine disruptor

[

[108][45]

Coronary heart disease

[109][46]

Liver toxicity

[110][47]

Hypertension

[111][48]

[

61

]

Diabetes and insulin resistance

Inhibition of glycolysis, Krebs’s cycle, and ATP synthesis

[125,126][62][63]

Acute Kidney Injury (AKI)

Kidney injury molecule-1 (KIM1)

[127][

Genotoxicity

[112][49]

Arsenite (AsIII)

Cancer

[113][50]

64

]

Fatty liver

[114][51]

Chronic kidney disease (CKD)

130

]

[67]

Lung cancer

DNA damage

[104,131][41]

Hepatotoxicity

[115][52]

Arsenic trioxide

Breast cancer

[116][53]
Chronic exposure to As produces harmful effects on the immune system. Immune responses depend on the proliferation of T and B cells as well as macrophages. Chronic exposure to As may cause immunosuppression by affecting cellular and humoral immunity [102,117][39][54]. It has been found that immunosuppression due to decreased T-cell proliferation is linked with low cytokine secretion, tumor necrosis factor (TNF)-α, interferon-γ, IL-2, IL-10, IL-5, and IL-4. A similar study states that chronic exposure leads to high serum immunoglobulin IgA, IgG, and IgE, which may lead to the development of respiratory complications such as pneumonia, allergic bronchitis, and chronic obstructive pulmonary disease [

Decreased glomerular filtration rate

[

68

]

Kidney cancer

DNA damage

[131][68]
As affects the gluconeogenesis in muscle cells by inhibiting glucose transporters and suppressing glucose metabolism regulatory genes. Hence, the glycolytic pathway and mitochondrial energy production are altered [132,133][69][70]. In experimental studies of mice, it has been reported that As decreases the functional capacity of muscle and destroys muscle progenitor cells [134][71]. Muscle damage occurs by inhibiting muscle repair and increasing the nuclear factor kappa light-chain enhancer of activated B cells (NF-κB), along with inflammation signaling, a long healing time, and fibrosis. Consequently, As exposure contributes to sarcopenia progression [135][72].
As acute toxicity generates oxidative stress and pro-inflammatory reactions in the epithelial cells of the intestine in in vivo studies [136,137][73][74]. Therefore, reactive oxygen species (ROS) damage the cytoskeleton and cause the loss of tight junction proteins such as claudin-5 and occludin in the blood–brain barrier [138][75]. iAs species might be liable to increase paracellular transport at tight junctions [139][76]. The high permeability of intestinal junctions is related to intestinal abnormalities such as dysbiosis, colitis, Crohn’s disease, ulcerative colitis, and other gastrointestinal complications [140][77]. High As levels increase colonies of pathogenic bacteria in dysbiosis, whereas low levels directly increase intestinal commensal bacteria. Therefore, gut microbiome health depends on a variety of species of probiotic bacteria [141][78]. A study conducted on children exposed to high As shows plenty of proteobacteria in stool samples [142][79]. A recent study on the Bangladeshi population demonstrated the toxic effect of high As on the species and flora of gut bacteria and the high number of pathogens [143][80]. Furthermore, it has also been seen that different forms of As species cross the blood–brain barrier, reducing neurotransmitters, including mono-amines and those associated with the cholinergic, dopaminergic, and glutamatergic systems, leading to damaged synaptic transmission [144][81]. Glutamate receptor expression inhibition may cause changes in synaptic plasticity, for instance, the long-term potentiation of learning and memory linked with enhancing extracellular glutamate levels [145][82]. Various diseases linked with As toxicity are depicted in Figure 1.
Figure 1. Arsenic exposure leads to acute to chronic complications such as chronic kidney disease, cardiovascular disease, schizophrenia, fatty liver, cirrhosis, dysbiosis, and different types of cancer.

3.2. Effects on Maternal Health

A recent study of As exposure and gestational diabetes mellitus (GDM) showed their strong positive links to each other [146][83]. Sung et al. reported a negative metabolic effect of As toxicity in GDM [126][63]. iAs changes glucose homeostasis by switching phosphates in adenosine triphosphate (ATP) synthesis and impairing ATP-dependent insulin. Furthermore, arsenate conjugates with the disulfide bridges of insulin, insulin receptors, glucose transporters (GLUTs), and glucose metabolism enzymes. Peroxisome proliferator-activated receptor γ (PPARγ) plays a significant role in the expression of insulin activation. As free radical damage interferes with the signal transduction and gene expression of β-cells, leading to the development of diabetes. As activates superoxide and binds with uncoupling protein 2 (UCP2), consequently decreasing insulin secretion [147][84]. UCP2 acts as a negative regulator for the secretion of insulin and also mediates proton leakage across the inner mitochondrial membrane [148][85].
In a research study on high exposure to As in Bangladeshi women, it was concluded that As exposure is the cause of cervical cancer (squamous cell carcinoma) [149][86]. Further, in another study of Bangladeshi women, it was found that As is also responsible for anemia. A prevalence of anemia has been found in the reproductive female age group and was linked to arsenicosis skin lesions [150][87]. High exposure to As also leads to early menopause of two years compared to low- or normal-limit exposed females’ menopausal stages [151][88]. In vivo and in vitro research of iAs exposure has revealed that As can attach to human and animal hemoglobin and can alter morphology, cell shape, levels of hemoglobin, and heme metabolism. Absorbed arsenic is transported through portal circulation via RBCs and WBCs. In another study, a 2–3-fold higher prevalence of anemia has been reported with a low dose of As-exposed drinking water compared to normal potable water, and pregnant women were more susceptible than non-pregnant women [152,153][89][90].
Ahmed et al. reported the effect on cellular innate immunity and immunosuppression of prenatal As exposure in Bangladeshi women [154][91]. The immune-suppressive effect on T and B cells as well as macrophages is due to the reduced expression of major histocompatibility complex (MHC) class II molecules, CD69, interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α). Inflammatory cascades of cytokine release low lymphocyte proliferation and IL-2 secretion, leading to inflammation, macrophage adhesion, phagocytosis, the increased apoptosis of peripheral blood mononuclear cells (PBMC), reduced ROS stimulus by PBMC, and stop the progress of the immunogenic response in hosts [102][39]. The disruption of estrogen receptors and the suppression of the signaling pathway of estrogen is linked to breast cancer, and As is a potential metallo-estrogen and acts as a medium to promote breast cancer [155,156,157][92][93][94]. Marciniak et al. (2020) reported in a Poland study that high-dose arsenic exposure increases the risk of breast cancer by 13 times compared to normal women [158][95].

3.3. Effects on Fetal and Neonatal Health

As exposure’s adverse effects have been reported also in neonatal health. It has been observed that arsenic exposure during the last trimester of pregnancy directly affects newborn telomere length (TL). Telomeres are DNA–protein structures; they are present at the end of each strand of DNA and defend the genome from nucleolytic degradation, interchromosomal fusion, and unnecessary recombination. Thus, telomeres exhibit a significant role to preserve information within the genome. Prenatal arsenic toxicity is the cause of newborn telomerase elongation and may suggest a new approach to neonatal health hazards [159][96]. Exposure to arsenic has harmful genotoxicity in newborns, DNA strand breaks, and increased MN frequency in cord blood. Increased arsenic maternal biomarkers are associated with genetic defects in newborns. Milton et al. (2017) reported the effect of As on spontaneous abortion and stillbirth, which are increased by up to 2–3-fold, and the risk of complications is 6-fold higher than in unexposed women. The ingestion of high arsenic content in food and water reduces methylation, which leads to folate deficiency and high homocysteine in urine, significantly contributing to congenital malformations and placental abruption [160,161,162][97][98][99].
Neural tube defects (NTDs) and insufficient neuron growth, as well as self-regulation in newborns, have been reported due to maternal As exposure [163,164][100][101]. Similar effects on newborns with high arsenic exposure were also reported in a Turkish study [165][102]. Deficits in memory, attention, and IQ from early life exposures are also noted with exposure to As [166][103]. Quansah et al. (2015) analyzed prospective birth cohort study results that indicate increased risks of spontaneous abortion, stillbirth, and neonatal and infant mortality among populations highly exposed to arsenic in drinking water. Chronic iAs exposure leads to placental insufficiency complications including preterm delivery and intrauterine growth retardation (IUGR) [154][91]. During pregnancy, As inorganic forms and their methylated metabolites cross the placenta and enter cord blood, leading to altered immune cell and gene expression in the cord blood of a highly exposed mother [167,168,169,170][104][105][106][107]. Moreover, other fetal complications also reported include slow fetal growth, low birth weight, and the effect of neuronal development in early life [89,171][26][108]. Many case-control and observation studies on As exposure have shown that it delays cognitive function and causes low intelligence quotients [172,173][109][110]. Children up to five years of age are more susceptible to arsenic exposure due to the high consumption of baby foods and more demand for energy and carbohydrate-rich diets. As-associated maternal and fetal complications can be seen in Figure 2.
Figure 2. Arsenic-induced maternal health complications such as anemia, early menopause, cervical and breast cancer, and child health complications including neural tube defects, DNA fragmentation, intrauterine growth retardation, and autism.

References

  1. Ezemonye, L.I.; Adebayo, P.O.; Enuneku, A.A.; Tongo, I.; Ogbomida, E. Potential health risk consequences of heavy metal concentrations in surface water, shrimp (Macrobrachium macrobrachion) and fish (Brycinus longipinnis) from Benin River, Nigeria. Toxicol. Rep. 2019, 6, 1–9.
  2. Hill-Briggs, F.; Adler, N.E.; Berkowitz, S.A.; Chin, M.H.; Gary-Webb, T.L.; Navas-Acien, A.; Thornton, P.L.; Haire-Joshu, D. Social determinants of health and diabetes: A scientific review. Diabetes Care 2021, 44, 258–279.
  3. Authority, E.F.S.; Arcella, D.; Cascio, C.; Gómez Ruiz, J.Á. Chronic dietary exposure to inorganic arsenic. EFSA J. 2021, 19, e06380.
  4. Chou, C.-H.; Harper, C. Toxicological Profile for Arsenic. 2007. Available online: https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/657856 (accessed on 1 March 2022).
  5. ATSDR (Agency for Toxic Substances and Disease Registry). Prepared by Clement International Corp., under contract 2000, 205, 88-0608.
  6. Wang, J.; Hu, W.; Yang, H.; Chen, F.; Shu, Y.; Zhang, G.; Liu, J.; Liu, Y.; Li, H.; Guo, L. Arsenic concentrations, diversity and co-occurrence patterns of bacterial and fungal communities in the feces of mice under sub-chronic arsenic exposure through food. Environ. Int. 2020, 138, 105600.
  7. Watanabe, T.; Hirano, S. Metabolism of arsenic and its toxicological relevance. Arch. Toxicol. 2013, 87, 969–979.
  8. Eckstein, M.; Eleazer, R.; Rea, M.; Fondufe-Mittendorf, Y. Epigenomic reprogramming in inorganic arsenic-mediated gene expression patterns during carcinogenesis. Rev. Environ. Health 2017, 32, 93–103.
  9. Alexander, J.; Benford, D.; Boobis, A.; Ceccatelli, S.; Cravedi, J.; di Domenico, A.; Doerge, D.; Dogliotti, E.; Edler, L.; Farmer, P.; et al. Scientific Opinion on marine biotoxins in shellfish—Palytoxin group. EFSA J. 2009, 7, 1393.
  10. Signes-Pastor, A.J.; Woodside, J.V.; McMullan, P.; Mullan, K.; Carey, M.; Karagas, M.R.; Meharg, A.A. Levels of infants’ urinary arsenic metabolites related to formula feeding and weaning with rice products exceeding the EU inorganic arsenic standard. PLoS ONE 2017, 12, e0176923.
  11. Molin, M.; Ulven, S.M.; Meltzer, H.M.; Alexander, J. Arsenic in the human food chain, biotransformation and toxicology–Review focusing on seafood arsenic. J. Trace Elem. Med. Biol. 2015, 31, 249–259.
  12. Yoshinaga, J.; Narukawa, T. Dietary intake and urinary excretion of methylated arsenicals of Japanese adults consuming marine foods and rice. Food Addit. Contam. Part A 2021, 38, 622–629.
  13. Tibon, J.; Silva, M.; Sloth, J.J.; Amlund, H.; Sele, V. Speciation analysis of organoarsenic species in marine samples: Method optimization using fractional factorial design and method validation. Anal. Bioanal. Chem. 2021, 413, 3909–3923.
  14. Taylor, V.F.; Jackson, B.P. Concentrations and speciation of arsenic in New England seaweed species harvested for food and agriculture. Chemosphere 2016, 163, 6–13.
  15. Sattar, A.; Xie, S.; Hafeez, M.A.; Wang, X.; Hussain, H.I.; Iqbal, Z.; Pan, Y.; Iqbal, M.; Shabbir, M.A.; Yuan, Z. Metabolism and toxicity of arsenicals in mammals. Environ. Toxicol. Pharmacol. 2016, 48, 214–224.
  16. Wang, D.; Shimoda, Y.; Wang, S.; Wang, Z.; Liu, J.; Liu, X.; Jin, H.; Gao, F.; Tong, J.; Yamanaka, K. Total arsenic and speciation analysis of saliva and urine samples from individuals living in a chronic arsenicosis area in China. Environ. Health Prev. Med. 2017, 22, 45.
  17. Zhang, Q.; Li, Y.; Liu, J.; Wang, D.; Zheng, Q.; Sun, G. Differences of urinary arsenic metabolites and methylation capacity between individuals with and without skin lesions in Inner Mongolia, Northern China. Int. J. Environ. Res. Public Health 2014, 11, 7319–7332.
  18. Roggenbeck, B.A.; Banerjee, M.; Leslie, E.M. Cellular arsenic transport pathways in mammals. J. Environ. Sci. 2016, 49, 38–58.
  19. Moe, B.; Peng, H.; Lu, X.; Chen, B.; Chen, L.W.; Gabos, S.; Li, X.-F.; Le, X.C. Comparative cytotoxicity of fourteen trivalent and pentavalent arsenic species determined using real-time cell sensing. J. Environ. Sci. 2016, 49, 113–124.
  20. Hubaux, R.; Becker-Santos, D.D.; Enfield, K.S.; Rowbotham, D.; Lam, S.; Lam, W.L.; Martinez, V.D. Molecular features in arsenic-induced lung tumors. Mol. Cancer 2013, 12, 1–11.
  21. Dheeman, D.S.; Packianathan, C.; Pillai, J.K.; Rosen, B.P. Pathway of human AS3MT arsenic methylation. Chem. Res. Toxicol. 2014, 27, 1979–1989.
  22. Roggenbeck, B.A.; Leslie, E.M.; Walk, S.T.; Schmidt, E.E. Redox metabolism of ingested arsenic: Integrated activities of microbiome and host on toxicological outcomes. Curr. Opin. Toxicol. 2019, 13, 90–98.
  23. Flora, S.J. Toxic metals: Health effects, and therapeutic measures. J. Biomed. Ther. Sci. 2014, 1, 48–64.
  24. Styblo, M.; Serves, S.V.; Cullen, W.R.; Thomas, D.J. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem. Res. Toxicol. 1997, 10, 27–33.
  25. Mishra, D.; Mehta, A.; Flora, S.J. Reversal of arsenic-induced hepatic apoptosis with combined administration of DMSA and its analogues in guinea pigs: Role of glutathione and linked enzymes. Chem. Res. Toxicol. 2008, 21, 400–407.
  26. Chakraborti, D.; Rahman, M.M.; Ahamed, S.; Dutta, R.N.; Pati, S.; Mukherjee, S.C. Arsenic groundwater contamination and its health effects in Patna district (capital of Bihar) in the middle Ganga plain, India. Chemosphere 2016, 152, 520–529.
  27. Hu, Y.; Xiao, T.; Zhang, A. Associations between and risks of trace elements related to skin and liver damage induced by arsenic from coal burning. Ecotoxicol. Environ. Saf. 2021, 208, 111719.
  28. Chervona, Y.; Arita, A.; Costa, M. Carcinogenic metals and the epigenome: Understanding the effect of nickel, arsenic, and chromium. Metallomics 2012, 4, 619–627.
  29. Calatayud, M.; Barrios, J.A.; Vélez, D.; Devesa, V. In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem. Res. Toxicol. 2012, 25, 446–453.
  30. Frediani, J.K.; Naioti, E.A.; Vos, M.B.; Figueroa, J.; Marsit, C.J.; Welsh, J.A. Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among US adolescents and adults: An association modified by race/ethnicity, NHANES 2005–2014. Environ. Health 2018, 17, 6.
  31. Bunderson, M.; Coffin, J.D.; Beall, H.D. Arsenic induces peroxynitrite generation and cyclooxygenase-2 protein expression in aortic endothelial cells: Possible role in atherosclerosis. Toxicol. Appl. Pharmacol. 2002, 184, 11–18.
  32. Chen, Y.; Factor-Litvak, P.; Howe, G.R.; Graziano, J.H.; Brandt-Rauf, P.; Parvez, F.; Van Geen, A.; Ahsan, H. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: A population-based, cross-sectional study. Am. J. Epidemiol. 2007, 165, 541–552.
  33. Bustaffa, E.; Stoccoro, A.; Bianchi, F.; Migliore, L. Genotoxic and epigenetic mechanisms in arsenic carcinogenicity. Arch. Toxicol. 2014, 88, 1043–1067.
  34. Tao, X.; Wang, N.; Qin, W. Gut microbiota and hepatocellular carcinoma. Gastrointest. Tumors 2015, 2, 33–40.
  35. Lu, K.; Abo, R.P.; Schlieper, K.A.; Graffam, M.E.; Levine, S.; Wishnok, J.S.; Swenberg, J.A.; Tannenbaum, S.R.; Fox, J.G. Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: An integrated metagenomics and metabolomics analysis. Environ. Health Perspect. 2014, 122, 284–291.
  36. Sinha, D.; Roy, M. Antagonistic role of tea against sodium arsenite-induced oxidative DNA damage and inhibition of DNA repair in Swiss albino mice. J. Environ. Pathol. Toxicol. Oncol. 2011, 30, 311–312.
  37. D’Ippoliti, D.; Santelli, E.; De Sario, M.; Scortichini, M.; Davoli, M.; Michelozzi, P. Arsenic in drinking water and mortality for cancer and chronic diseases in Central Italy, 1990-2010. PLoS ONE 2015, 10, e0138182.
  38. Abdul, K.S.M.; Jayasinghe, S.S.; Chandana, E.P.; Jayasumana, C.; de Silva, P.M.C. Arsenic and human health effects: A review. Environ. Toxicol. Pharmacol. 2015, 40, 828–846.
  39. Dangleben, N.L.; Skibola, C.F.; Smith, M.T. Arsenic immunotoxicity: A review. Environ. Health 2013, 12, 73.
  40. Rehman, M.Y.A.; Briedé, J.J.; van Herwijnen, M.; Krauskopf, J.; Jennen, D.G.; Malik, R.N.; Kleinjans, J.C. Integrating SNPs-based genetic risk factor with blood epigenomic response of differentially arsenic-exposed rural subjects reveals disease-associated signaling pathways. Environ. Pollut. 2022, 292, 118279.
  41. Martinez, V.D.; Vucic, E.A.; Adonis, M.; Gil, L.; Lam, W.L. Arsenic biotransformation as a cancer promoting factor by inducing DNA damage and disruption of repair mechanisms. Mol. Biol. Int. 2011, 2011, 718974.
  42. Soni, M.; Prakash, C.; Sehwag, S.; Kumar, V. Protective effect of hydroxytyrosol in arsenic-induced mitochondrial dysfunction in rat brain. J. Biochem. Mol. Toxicol. 2017, 31, e21906.
  43. Akbal, A.; Yılmaz, H.; Tutkun, E. Arsenic exposure associated with decreased bone mineralization in male. Aging Male 2014, 17, 256–258.
  44. Singh, M.K.; Dwivedi, S.; Yadav, S.S.; Yadav, R.S.; Khattri, S. Anti-diabetic effect of Emblica officinalis (Amla) against arsenic induced metabolic disorder in mice. Indian J. Clin. Biochem. 2020, 35, 179–187.
  45. Carlson, P.; van Beneden, R.J. Arsenic exposure alters expression of cell cycle and lipid metabolism genes in the liver of adult zebrafish (Danio rerio). Aquat. Toxicol. 2014, 153, 66–72.
  46. Afolabi, O.K.; Wusu, A.D.; Ogunrinola, O.O.; Abam, E.O.; Babayemi, D.O.; Dosumu, O.; Onunkwor, O.; Balogun, E.; Odukoya, O.O.; Ademuyiwa, O. Arsenic-induced dyslipidemia in male albino rats: Comparison between trivalent and pentavalent inorganic arsenic in drinking water. BMC Pharmacol. Toxicol. 2015, 16, 15.
  47. Souza, A.; Bastos, D.; Sertorio, M.; Santos, F.; Ervilha, L.; de Oliveira, L.; Machado-Neves, M. Combined effects of arsenic exposure and diabetes on male reproductive functions. Andrology 2019, 7, 730–740.
  48. Wang, X.; Wu, Y.; Sun, X.; Guo, Q.; Xia, W.; Wu, Y.; Li, J.; Xu, S.; Li, Y. Arsenic exposure and metabolism in relation to blood pressure changes in pregnant women. Ecotoxicol. Environ. Saf. 2021, 222, 112527.
  49. Faita, F.; Cori, L.; Bianchi, F.; Andreassi, M.G. Arsenic-induced genotoxicity and genetic susceptibility to arsenic-related pathologies. Int. J. Environ. Res. Public Health 2013, 10, 1527–1546.
  50. Tokar, E.J.; Benbrahim-Tallaa, L.; Ward, J.M.; Lunn, R.; Sams, R.L.; Waalkes, M.P. Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit. Rev. Toxicol. 2010, 40, 912–927.
  51. Fatoki, J.O.; Badmus, J.A. Arsenic as an environmental and human health antagonist: A review of its toxicity and disease initiation. J. Hazard. Mater. Adv. 2022, 100052.
  52. Xu, P.; Liu, A.; Li, F.; Tinkov, A.A.; Liu, L.; Zhou, J.-C. Associations between metabolic syndrome and four heavy metals: A systematic review and meta-analysis. Environ. Pollut. 2021, 273, 116480.
  53. Li, G.; Sun, G.-X.; Williams, P.N.; Nunes, L.; Zhu, Y.-G. Inorganic arsenic in Chinese food and its cancer risk. Environ. Int. 2011, 37, 1219–1225.
  54. Biswas, R.; Ghosh, P.; Banerjee, N.; Das, J.; Sau, T.; Banerjee, A.; Roy, S.; Ganguly, S.; Chatterjee, M.; Mukherjee, A. Analysis of T-cell proliferation and cytokine secretion in the individuals exposed to arsenic. Hum. Exp. Toxicol. 2008, 27, 381–386.
  55. Islam, L.N.; Nurun Nabi, A.; Rahman, M.M.; Zahid, M.S.H. Association of respiratory complications and elevated serum immunoglobulins with drinking water arsenic toxicity in human. J. Environ. Sci. Health Part A 2007, 42, 1807–1814.
  56. Robles-Osorio, M.L.; Sabath-Silva, E.; Sabath, E. Arsenic-mediated nephrotoxicity. Ren. Fail. 2015, 37, 542–547.
  57. Li, Z.; Piao, F.; Liu, S.; Wang, Y.; Qu, S. Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice. Exp. Toxicol. Pathol. 2010, 62, 543–547.
  58. Hossain, E.; Ota, A.; Takahashi, M.; Karnan, S.; Damdindorj, L.; Konishi, Y.; Konishi, H.; Hosokawa, Y. Arsenic upregulates the expression of angiotensin II Type I receptor in mouse aortic endothelial cells. Toxicol. Lett. 2013, 220, 70–75.
  59. Li, L.; Bi, Z.; Wadgaonkar, P.; Lu, Y.; Zhang, Q.; Fu, Y.; Thakur, C.; Wang, L.; Chen, F. Metabolic and Epigenetic Reprogramming in the Arsenic-Induced Cancer Stem Cells. In Proceedings of the Seminars in Cancer Biology; Academic Press: Cambridge, MA, USA, 2019; pp. 10–18.
  60. Muzaffar, S.; Khan, J.; Srivastava, R.; Gorbatyuk, M.S.; Athar, M. Mechanistic understanding of the toxic effects of arsenic and warfare arsenicals on human health and environment. Cell Biol. Toxicol. 2022, 1–26.
  61. Xu, L.; Polya, D.A.; Li, Q.; Mondal, D. Association of low-level inorganic arsenic exposure from rice with age-standardized mortality risk of cardiovascular disease (CVD) in England and Wales. Sci. Total Environ. 2020, 743, 140534.
  62. Kulshrestha, A.; Jarouliya, U.; Prasad, G.; Flora, S.; Bisen, P.S. Arsenic-induced abnormalities in glucose metabolism: Biochemical basis and potential therapeutic and nutritional interventions. World J. Transl. Med. 2014, 3, 96–111.
  63. Sung, T.-C.; Huang, J.-W.; Guo, H.-R. Association between arsenic exposure and diabetes: A meta-analysis. BioMed Res. Int. 2015, 2015.
  64. Cárdenas-González, M.; Osorio-Yáñez, C.; Gaspar-Ramírez, O.; Pavković, M.; Ochoa-Martinez, A.; López-Ventura, D.; Medeiros, M.; Barbier, O.; Pérez-Maldonado, I.; Sabbisetti, V. Environmental exposure to arsenic and chromium in children is associated with kidney injury molecule-1. Environ. Res. 2016, 150, 653–662.
  65. Hsu, L.-I.; Hsieh, F.-I.; Wang, Y.-H.; Lai, T.-S.; Wu, M.-M.; Chen, C.-J.; Chiou, H.-Y.; Hsu, K.-H. Arsenic exposure from drinking water and the incidence of CKD in low to moderate exposed areas of Taiwan: A 14-year prospective study. Am. J. Kidney Dis. 2017, 70, 787–797.
  66. Li, W.; Wu, L.; Sun, Q.; Yang, Q.; Xue, J.; Shi, M.; Tang, H.; Zhang, J.; Liu, Q. MicroRNA-191 blocking the translocation of GLUT4 is involved in arsenite-induced hepatic insulin resistance through inhibiting the IRS1/AKT pathway. Ecotoxicol. Environ. Saf. 2021, 215, 112130.
  67. López-Carrillo, L.; Hernández-Ramírez, R.U.; Gandolfi, A.J.; Ornelas-Aguirre, J.M.; Torres-Sánchez, L.; Cebrian, M.E. Arsenic methylation capacity is associated with breast cancer in northern Mexico. Toxicol. Appl. Pharmacol. 2014, 280, 53–59.
  68. Smith, N.K.; Keltie, E.; Sweeney, E.; Weerasinghe, S.; MacPherson, K.; Kim, J.S. Toenail speciation biomarkers in arsenic-related disease: A feasibility study for investigating the association between arsenic exposure and chronic disease. Ecotoxicol. Environ. Saf. 2022, 232, 113269.
  69. Díaz-Villaseñor, A.; Burns, A.L.; Hiriart, M.; Cebrián, M.E.; Ostrosky-Wegman, P. Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol. Appl. Pharmacol. 2007, 225, 123–133.
  70. Sarker, M.; Tony, S.R.; Siddique, A.E.; Karim, M.; Haque, N.; Islam, Z.; Islam, M.; Khatun, M.; Islam, J.; Hossain, S. Arsenic secondary methylation capacity is inversely associated with arsenic exposure-related muscle mass reduction. Int. J. Environ. Res. Public Health 2021, 18, 9730.
  71. Ambrosio, F.; Brown, E.; Stolz, D.; Ferrari, R.; Goodpaster, B.; Deasy, B.; Distefano, G.; Roperti, A.; Cheikhi, A.; Garciafigueroa, Y. Arsenic induces sustained impairment of skeletal muscle and muscle progenitor cell ultrastructure and bioenergetics. Free. Radic. Biol. Med. 2014, 74, 64–73.
  72. Zhang, C.; Ferrari, R.; Beezhold, K.; Stearns-Reider, K.; D’Amore, A.; Haschak, M.; Stolz, D.; Robbins, P.D.; Barchowsky, A.; Ambrosio, F. Arsenic promotes NF-κB-mediated fibroblast dysfunction and matrix remodeling to impair muscle stem cell function. Stem Cells 2016, 34, 732–742.
  73. Calatayud, M.; Devesa, V.; Vélez, D. Differential toxicity and gene expression in Caco-2 cells exposed to arsenic species. Toxicol. Lett. 2013, 218, 70–80.
  74. Calatayud, M.; Gimeno-Alcañiz, J.V.; Devesa, V.; Vélez, D. Proinflammatory effect of trivalent arsenical species in a co-culture of Caco-2 cells and peripheral blood mononuclear cells. Arch. Toxicol. 2015, 89, 555–564.
  75. Schreibelt, G.; Kooij, G.; Reijerkerk, A.; van Doorn, R.; Gringhuis, S.I.; van der Pol, S.; Weksler, B.B.; Romero, I.A.; Couraud, P.O.; Piontek, J. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J. 2007, 21, 3666–3676.
  76. Capaldo, C.T.; Nusrat, A. Cytokine regulation of tight junctions. Biochim. Biophys. Acta Biomembr. 2009, 1788, 864–871.
  77. Groschwitz, K.R.; Hogan, S.P. Intestinal barrier function: Molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 2009, 124, 3–20.
  78. Ashraf, S.A.; Elkhalifa, A.E.O.; Ahmad, M.F.; Patel, M.; Adnan, M.; Sulieman, A.M.E. Probiotic Fermented Foods and Health Promotion. In African Fermented Food Products-New Trends; Springer: Berlin/Heildeberg, Germany, 2022; pp. 59–88.
  79. Dong, X.; Shulzhenko, N.; Lemaitre, J.; Greer, R.L.; Peremyslova, K.; Quamruzzaman, Q.; Rahman, M.; Hasan, O.S.I.; Joya, S.A.; Golam, M. Arsenic exposure and intestinal microbiota in children from Sirajdikhan, Bangladesh. PLoS ONE 2017, 12, e0188487.
  80. Wu, F.; Yang, L.; Islam, M.T.; Jasmine, F.; Kibriya, M.G.; Nahar, J.; Barmon, B.; Parvez, F.; Sarwar, G.; Ahmed, A. The role of gut microbiome and its interaction with arsenic exposure in carotid intima-media thickness in a Bangladesh population. Environ. Int. 2019, 123, 104–113.
  81. Yadav, R.S.; Shukla, R.K.; Sankhwar, M.L.; Patel, D.K.; Ansari, R.W.; Pant, A.B.; Islam, F.; Khanna, V.K. Neuroprotective effect of curcumin in arsenic-induced neurotoxicity in rats. Neurotoxicology 2010, 31, 533–539.
  82. Ramos-Chávez, L.A.; Rendón-López, C.R.; Zepeda, A.; Silva-Adaya, D.; Del Razo, L.M.; Gonsebatt, M.E. Neurological effects of inorganic arsenic exposure: Altered cysteine/glutamate transport, NMDA expression and spatial memory impairment. Front. Cell. Neurosci. 2015, 2015, 21.
  83. Salmeri, N.; Villanacci, R.; Ottolina, J.; Bartiromo, L.; Cavoretto, P.; Dolci, C.; Lembo, R.; Schimberni, M.; Valsecchi, L.; Viganò, P. Maternal arsenic exposure and gestational diabetes: A systematic review and meta-analysis. Nutrients 2020, 12, 3094.
  84. Tseng, C.-H. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol. Appl. Pharmacol. 2004, 197, 67–83.
  85. Seshadri, N.; Jonasson, M.E.; Hunt, K.L.; Xiang, B.; Cooper, S.; Wheeler, M.B.; Dolinsky, V.W.; Doucette, C.A. Uncoupling protein 2 regulates daily rhythms of insulin secretion capacity in MIN6 cells and isolated islets from male mice. Mol. Metab. 2017, 6, 760–769.
  86. Mostafa, M.G.; Queen, Z.J.; Cherry, N. Histopathology of cervical cancer and arsenic concentration in well water: An ecological analysis. Int. J. Environ. Res. Public Health 2017, 14, 1185.
  87. Kile, M.L.; Faraj, J.M.; Ronnenberg, A.G.; Quamruzzaman, Q.; Rahman, M.; Mostofa, G.; Afroz, S.; Christiani, D.C. A cross sectional study of anemia and iron deficiency as risk factors for arsenic-induced skin lesions in Bangladeshi women. BMC Public Health 2016, 16, 158.
  88. Yunus, F.M.; Rahman, M.J.; Alam, M.Z.; Hore, S.K.; Rahman, M. Relationship between arsenic skin lesions and the age of natural menopause. BMC Public Health 2014, 14, 419.
  89. Surdu, S.; Bloom, M.S.; Neamtiu, I.A.; Pop, C.; Anastasiu, D.; Fitzgerald, E.F.; Gurzau, E.S. Consumption of arsenic-contaminated drinking water and anemia among pregnant and non-pregnant women in northwestern Romania. Environ. Res. 2015, 140, 657–660.
  90. Breton, C.V.; Houseman, E.A.; Kile, M.L.; Quamruzzaman, Q.; Rahman, M.; Mahiuddin, G.; Christiani, D.C. Gender-specific protective effect of hemoglobin on arsenic-induced skin lesions. Cancer Epidemiol. Prev. Biomark. 2006, 15, 902–907.
  91. Ahmed, S.; Khoda, S.M.-e.; Rekha, R.S.; Gardner, R.M.; Ameer, S.S.; Moore, S.; Ekström, E.-C.; Vahter, M.; Raqib, R. Arsenic-associated oxidative stress, inflammation, and immune disruption in human placenta and cord blood. Environ. Health Perspect. 2011, 119, 258–264.
  92. Davey, J.C.; Bodwell, J.E.; Gosse, J.A.; Hamilton, J.W. Arsenic as an endocrine disruptor: Effects of arsenic on estrogen receptor–mediated gene expression in vivo and in cell culture. Toxicol. Sci. 2007, 98, 75–86.
  93. Chatterjee, A.; Chatterji, U. Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod. Biol. Endocrinol. 2010, 8, 80.
  94. Aquino, N.B.; Sevigny, M.B.; Sabangan, J.; Louie, M.C. The role of cadmium and nickel in estrogen receptor signaling and breast cancer: Metalloestrogens or not? J. Environ. Sci. Health Part C 2012, 30, 189–224.
  95. Marciniak, W.; Derkacz, R.; Muszyńska, M.; Baszuk, P.; Gronwald, J.; Huzarski, T.; Cybulski, C.; Jakubowska, A.; Falco, M.; Dębniak, T. Blood arsenic levels and the risk of familial breast cancer in Poland. Int. J. Cancer 2020, 146, 2721–2727.
  96. Song, L.; Liu, B.; Zhang, L.; Wu, M.; Wang, L.; Cao, Z.; Zhang, B.; Li, Y.; Wang, Y.; Xu, S. Association of prenatal exposure to arsenic with newborn telomere length: Results from a birth cohort study. Environ. Res. 2019, 175, 442–448.
  97. Pilsner, J.R.; Hall, M.N.; Liu, X.; Ilievski, V.; Slavkovich, V.; Levy, D.; Factor-Litvak, P.; Yunus, M.; Rahman, M.; Graziano, J.H. Influence of prenatal arsenic exposure and newborn sex on global methylation of cord blood DNA. PLoS ONE 2012, 7, e37147.
  98. Milton, A.H.; Hussain, S.; Akter, S.; Rahman, M.; Mouly, T.A.; Mitchell, K. A review of the effects of chronic arsenic exposure on adverse pregnancy outcomes. Int. J. Environ. Res. Public Health 2017, 14, 556.
  99. He, Y.; Pan, A.; Hu, F.B.; Ma, X. Folic acid supplementation, birth defects, and adverse pregnancy outcomes in Chinese women: A population-based mega-cohort study. Lancet 2016, 388, S91.
  100. Mazumdar, M.; Hasan, M.O.S.I.; Hamid, R.; Valeri, L.; Paul, L.; Selhub, J.; Rodrigues, E.G.; Silva, F.; Mia, S.; Mostofa, M.G. Arsenic is associated with reduced effect of folic acid in myelomeningocele prevention: A case control study in Bangladesh. Environ. Health 2015, 14, 34.
  101. Parajuli, R.P.; Fujiwara, T.; Umezaki, M.; Watanabe, C. Association of cord blood levels of lead, arsenic, and zinc with neurodevelopmental indicators in newborns: A birth cohort study in Chitwan Valley, Nepal. Environ. Res. 2013, 121, 45–51.
  102. Demir, N.; Başaranoğlu, M.; Huyut, Z.; Değer, İ.; Karaman, K.; Şekeroğlu, M.R.; Tuncer, O. The relationship between mother and infant plasma trace element and heavy metal levels and the risk of neural tube defect in infants. J. Matern. Fetal Neonatal Med. 2019, 32, 1433–1440.
  103. Tolins, M.; Ruchirawat, M.; Landrigan, P. The developmental neurotoxicity of arsenic: Cognitive and behavioral consequences of early life exposure. Ann. Glob. Health 2014, 80, 303–314.
  104. Nadeau, K.C.; Li, Z.; Farzan, S.; Koestler, D.; Robbins, D.; Fei, D.L.; Malipatlolla, M.; Maecker, H.; Enelow, R.; Korrick, S. In utero arsenic exposure and fetal immune repertoire in a US pregnancy cohort. Clin. Immunol. 2014, 155, 188–197.
  105. Farzan, S.F.; Korrick, S.; Li, Z.; Enelow, R.; Gandolfi, A.J.; Madan, J.; Nadeau, K.; Karagas, M.R. In utero arsenic exposure and infant infection in a United States cohort: A prospective study. Environ. Res. 2013, 126, 24–30.
  106. Jiang, C.-B.; Hsi, H.-C.; Fan, C.-H.; Chien, L.-C. Fetal exposure to environmental neurotoxins in Taiwan. PLoS ONE 2014, 9, e109984.
  107. Vahter, M. Effects of arsenic on maternal and fetal health. Annu. Rev. Nutr. 2009, 29, 381–399.
  108. Bae, S.; Kamynina, E.; Farinola, A.F.; Caudill, M.A.; Stover, P.J.; Cassano, P.A.; Berry, R.; Peña-Rosas, J.P. Provision of folic acid for reducing arsenic toxicity in arsenic-exposed children and adults. Cochrane Database Syst. Rev. 2017, CD012649.
  109. Arroyo, H.A.; Fernández, M.C. Tóxicos ambientales y su efecto sobre el neurodesarrollo. Medicina 2013, 73.
  110. Yorifuji, T.; Kato, T.; Ohta, H.; Bellinger, D.C.; Matsuoka, K.; Grandjean, P. Neurological and neuropsychological functions in adults with a history of developmental arsenic poisoning from contaminated milk powder. Neurotoxicol. Teratol. 2016, 53, 75–80.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback